Halozyme, Inc.

Halozyme, Inc. is a biotechnology company focused on developing and commercializing innovative drug delivery technologies and specialty pharmaceuticals. Their primary technology is based on their proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20), which enhances the subcutaneous delivery of drugs and fluids by temporarily breaking down hyaluronan, a natural barrier in the skin. This technology has the potential to significantly improve patient experiences by reducing the need for IV infusions and offering greater convenience and ease of administration.

In addition to their core ENHANZE® drug delivery technology, Halozyme markets and commercializes two FDA-approved products featuring their unique development and delivery technologies: HYLENEX® (recombinant hyaluronidase human injection) and XYOSTED® (testosterone enanthate). Halozyme is committed to providing patients with safe and effective therapies that improve their quality of life, while also prioritizing innovation and building a diverse and inclusive team culture.

Halozyme offers a hybrid work model, enabling employees to balance their professional and personal lives. This allows for flexibility in working hours and location, promoting a healthy work-life balance. The company also provides generous paid time off, holidays, including a winter closure, and paid parental leave, further supporting employees' well-being and enabling them to recharge and find balance.

Halozyme offers a comprehensive benefits package designed to support employee well-being and growth. Benefits include a hybrid working model, comprehensive health insurance, paid time off, sick leave, and holidays, including a winter closure. Employees are eligible for equity awards and a discount on Halozyme stock through the Employee Stock Purchase Plan. To help with retirement planning, the company offers a 401(k) plan with a company match. Additionally, Halozyme provides paid parental and pregnancy leave, educational assistance, and multiple forms of income protection for unexpected situations.

Halozyme is focused on developing and delivering disruptive solutions that aim to significantly improve the patient experience, potentially outcomes, for both emerging and established therapies. Their primary mission is to provide innovative and accessible treatment options by utilizing their proprietary drug delivery technologies and a robust commercial portfolio.

Halozyme fosters a team-oriented culture that values diversity, collaboration, and respect. The company encourages its employees to bring their unique perspectives to the table, creating an environment where innovation thrives. They are committed to supporting their employees through comprehensive benefits, wellness programs, and professional development opportunities, promoting a strong work-life balance. Their focus on community engagement reinforces their dedication to making a positive impact on the world, going beyond just business and into a realm of social responsibility.

Halozyme is committed to building a diverse and inclusive workplace by integrating diversity, equity, and inclusion (DE&I) into its core processes. The company aims to reflect the rich tapestry of global talent, recognizing that diversity fosters innovation and a culture of creativity, collaboration, and excellence. This is achieved through inclusive hiring practices, development programs, and equitable pay, as well as reinforcing DE&I topics in its Elevate leadership training curriculum. Halozyme has adopted the Biotechnology Innovation Organization’s principles on workforce development, diversity, and inclusion as a guide in its efforts to create a welcoming and inclusive work environment for all.